European Commission Grants Conditional Approval of CARVYKTI ® (Ciltacabtagene Autoleucel), Janssen’s First Cell Therapy, for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
BEERSE, BELGIUM, 26 May 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission (EC) granted conditional marketing authorisation of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed and refractory multiple myeloma (RRMM) who have received at least three prior therapies, including an immunomodulatory agent (IMiD), a proteasome inhibitor (PI) and an anti-CD38 antibody, and have demonstrated disease progression on the last therapy. In December 2017, Janssen Biotech, Inc. (Janssen) entered into an exclusive worldwide license a...
Source: Johnson and Johnson - May 26, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Medicaid Survival Boost; Big Myeloma Improvement; Clozapine-Cancer Link
(MedPage Today) -- Medicaid expansion under the Affordable Care Act was associated with significantly improved cancer survival, particularly among non-Hispanic Blacks and people living in rural areas. (American Cancer Society, Journal of the National... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - May 20, 2022 Category: Hematology Source Type: news
Elotuzumab Combination Disappoints in Newly Diagnosed Myeloma
(MedPage Today) -- Adding the monoclonal antibody elotuzumab (Empliciti) to lenalidomide (Revlimid) and dexamethasone failed to improve outcomes for patients with newly diagnosed, transplant-ineligible multiple myeloma, a phase III trial showed... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - May 12, 2022 Category: Hematology Source Type: news
The Added Value of Flow Cytometry in CAR T-Cell Clinical Trials,...
In this free webinar, learn about CAR T-cell monitoring in multiple myeloma (MM) trials. Attendees will learn about flow assay design to monitor CAR T cells in patients and the challenges in flow...(PRWeb May 10, 2022)Read the full story at https://www.prweb.com/releases/the_added_value_of_flow_cytometry_in_car_t_cell_clinical_trials_upcoming_webinar_hosted_by_xtalks/prweb18667281.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - May 10, 2022 Category: Pharmaceuticals Source Type: news
Johnson & Johnson Reports Q1 2022 Results
New Brunswick, N.J. (April 19, 2022) – Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2022. “Our first quarter results demonstrate strong performance across the enterprise, despite macro-economic headwinds. I am incredibly proud of Johnson & Johnson’s 144,000 employees for their relentless passion and Credo-based commitment to delivering transformative healthcare solutions to patients and customers around the world,” said Joaquin Duato, Chief Executive Officer. “Looking ahead, I remain confident in the future of Johnson & Johnson as we continue advancing our portfolio and inno...
Source: Johnson and Johnson - April 19, 2022 Category: Pharmaceuticals Tags: Financial Source Type: news
Third Dose of COVID-19 Vaccine Significantly Increases Immune...
Most immunocompromised people with a blood cancer called multiple myeloma benefited from a third dose of COVID-19 vaccines, a promising sign after it was shown that two doses tended to not be...(PRWeb April 06, 2022)Read the full story at https://www.prweb.com/releases/third_dose_of_covid_19_vaccine_significantly_increases_immune_responses_in_most_patients_with_multiple_myeloma/prweb18604314.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - April 6, 2022 Category: Pharmaceuticals Source Type: news
PET/CT can reduce mediastinal cancer biopsies
PET/CT scans can help prevent the use of invasive biopsies in patients wit...Read more on AuntMinnie.comRelated Reading:
PET visualizes early atherosclerosis
PET/CT predicts treatment outcomes in myeloma patients
PET/CT proves value diagnosing fevers of unknown origin
FAPI-PET may improve diagnosis of gastric cancer
Ga-68 radiotracer outperforms F-18 FDG in lung cancer staging (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - April 5, 2022 Category: Radiology Source Type: news
Is Multiple Myeloma Genetic or Hereditary?
Title: Is Multiple Myeloma Genetic or Hereditary?Category: Diseases and ConditionsCreated: 4/1/2022 12:00:00 AMLast Editorial Review: 4/1/2022 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - April 1, 2022 Category: Cancer & Oncology Source Type: news
Transplant, new model of care give hope to Salvadoran mom after cancer diagnosis
When Veronica Ciudad-Real was diagnosed with multiple myeloma — a blood cancer she had never heard of — in early 2021, the single mother had more questions than answers. At 40, she was younger than most patients diagnosed with the disease. Then she learned that the treatment she needed most was unavailable in her home country of El Salvador. Amid a pandemi c, Veronica would have to leave her home and her 14-year-old daughter to receive… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - March 31, 2022 Category: Databases & Libraries Source Type: news
Who Mostly Gets Multiple Myeloma
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - March 25, 2022 Category: General Medicine Source Type: news
Moving science forward: Experts convene for third Miami Cancer Institute Summit of the Americas on Immunotherapies for Hematologic Malignancies
In the United States, approximately 186,400 people are expected to be diagnosed with leukemia, lymphoma, myeloma and other blood cancers this year, according to the American Cancer Society. Thousands more are already in treatment. In April 2022, some of the nation ’s top experts will gather for the third Miami Cancer Institute Summit of Americas on Immunotherapies for Hematologic Malignancies to discuss the advances in immunologically and molecular based system therapies, new-targeted diagnostic… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - March 17, 2022 Category: American Health Authors: Baptist Health South Florida Source Type: news
Mayo Clinic Q & amp;A podcast: Advances in treating multiple myeloma help extend quality of life for patients
Multiple myeloma is a cancer that forms in a type of white blood cell called a plasma cell. Healthy plasma cells help the body fight infections by making antibodies that recognize and attack germs. In multiple myeloma, cancerous plasma cells accumulate in the bone marrow and crowd out healthy blood cells. Rather than produce helpful antibodies, the cancer cells produce abnormal proteins that can cause complications. Immunotherapy, which uses the body's immune system to fight… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - March 14, 2022 Category: Databases & Libraries Source Type: news
Patients With Multiple Myeloma Face Some Unique Sexual Challenges Patients With Multiple Myeloma Face Some Unique Sexual Challenges
Investigators urge clinicians to discuss patients ' sexual concerns. The study covered in this summary was published as a preprint and has not yet been peer reviewed.First Look (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 10, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
PET/CT predicts treatment outcomes in myeloma patients
PET/CT can help predict which patients have better chances of survival afte...Read more on AuntMinnie.comRelated Reading:
Photon-counting CT bests conventional scanners
PET/CT detects major depression in cancer patients
Small study supports radiation before CAR-T therapy
New radiotracer increases multiple myeloma survival (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 9, 2022 Category: Radiology Source Type: news
FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma
FDA approved ciltacabtagene autoleucel (CARVYKTI, Janssen Biotech, Inc.) for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 1, 2022 Category: Drugs & Pharmacology Authors: FDA Source Type: news
